光免疫偶联物的研究进展  

Study of Photoimmunoconjugates

作　　者：黄蕾[1] 赵福群[1] 黄新[1] 张复实[1] 

机构地区：[1]清华大学化学系有机光电子与分子工程教育部重点实验室,北京100084

出　　处：《化学进展》2007年第4期527-534,共8页Progress in Chemistry

基　　金：国家自然科学基金项目(No.203330802;0572059;20502013)资助

摘　　要：光敏剂与单克隆抗体交联可形成光免疫偶联物,这种偶联物具有识别肿瘤部位的能力。该方法解决了传统光动力疗法在癌症治疗中的低选择性问题。光免疫疗法的实现取决于在保证抗体活性的条件下使大量的光敏剂与抗体交联。本文回顾了光免疫疗法的发展过程,总结了目前常用的各种光免疫偶联物的制备方法和应用,并针对目前光免疫偶联物的应用现状,分析了未来的发展趋势,包括如何增强光敏剂的光敏化能力及提高靶向性的方法和途径。A photosensitizer coupled to the monoclonal antibody （MAb） can form photoimmunoconjugate, which has the capability of recognizing tumors. This method overcomes the limitation of low selectivity in the traditional photodynamic therapy of cancers. The development of photoimmunotherapy is reviewed in this paper. For photoimmunotherapy to be successful, sufficient amounts of sensitizer should be coupled to the MAb without altering its biological properties. Recent progress in the synthetic methods and the applications of photoimmunoconjugates are summarized briefly. Based on the applications in the photoimmunotherapy of photoimmunoconjugates, the trends of further development are described including approaches and methods of increasing the photosensitizing capability of photosensitizers and improving the ability of photoimmunoconjugates directly targeting tumors.

关 键 词：光免疫偶联物 光免疫疗法 光敏剂 单克隆抗体 

分 类 号：O621.33[理学—有机化学] O644.19[理学—化学]